Methylene blue dye as a single tracer for sentinel lymph node biopsy in early breast cancer

Vishwanath Patil; Garima Agarwal; Shalu Gupta; Raksha R. Thobbi; Sandesh Shettigar; Ayushi Agarwal; Anushka Goyal

doi:10.18203/2320-6012.ijrms20263113

Authors

Vishwanath Patil Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Garima Agarwal Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Shalu Gupta Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Raksha R. Thobbi Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Sandesh Shettigar Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Ayushi Agarwal Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India
Anushka Goyal Department of General Surgery, S. M. S. Medical College, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263113

Keywords:

Sentinel lymph node biopsy, Methylene blue dye, Breast cancer, Axillary lymph node dissection, Resource-constrained settings

Abstract

Background: Sentinel lymph node biopsy (SLNB) can reduce the morbidity of axillary lymph node dissection (ALND) in clinically node-negative breast cancer, but dual-tracer SLNB requires nuclear medicine infrastructure that is unavailable in many Indian hospitals. We evaluated 1% methylene blue dye (MBD) as a single tracer for SLNB in a resource-constrained setting.

Methods: In this prospective observational study, 30 women with clinically node-negative, early-stage breast cancer (T1-T2, N0, M0) underwent periareolar injection of 3 ml of 1% MBD during modified radical mastectomy. Sentinel lymph node(s) were identified and harvested separately during axillary dissection, followed by complete axillary lymph node dissection in all patients during our unit’s learning phase for histopathological validation.

Results: A sentinel node was identified in 29 of 30 patients (96.67%). Among these 29 patients, sensitivity was 88.89%, specificity 95.00%, positive predictive value 88.89%, negative predictive value 95.00%, and overall accuracy 93.10%. The false-negative rate was 11.11%. No anaphylaxis, skin necrosis, allergic reaction, or wound complication occurred. Three patients (10.0%) developed transient skin tattooing that resolved spontaneously.

Conclusions: MBD-only SLNB achieved a high identification rate and diagnostic accuracy during the learning phase, with no major adverse events. It may provide a pragmatic, low-cost alternative for axillary staging where radioisotope-based SLNB is unavailable. Larger multicentre studies are required before ALND can be safely omitted after a negative MBD-only SLNB.

References

Mathur P, Sathishkumar K, Chaturvedi M. Cancer statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063-75.

Zahoor S, Haji A, Battoo A. Sentinel lymph node biopsy in breast cancer: a clinical review and update. J Breast Cancer. 2017;20(3):217-27.

Morton DL, Wen DR, Wong JH. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-9.

Krag DN, Weaver D, Alex J. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335-9.

Mansel RE, Fallowfield L, Kissin M. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599-609.

Saha MM, Hossain MM, Saha S. The role of sentinel lymph node biopsy in the management of breast cancer. J Bangladesh Coll Phys Surg. 2015;32:211-217.

Perenyei M, Barber ZE, Gibson J, Hemington-Gorse S, Dobbs TD. Anaphylactic Reaction Rates to Blue Dyes Used for Sentinel Lymph Node Mapping: Systematic Review and Meta-analysis. Ann Surg. 2021;273(6):1087-93.

Nour A. Efficacy of methylene blue dye in localization of sentinel lymph node in breast cancer patients. Breast J. 2004;10(5):388-91.

Varghese P, Abdel-Rahman AT, Akberali S. Methylene blue dye-a safe and effective alternative for sentinel lymph node localization. Breast J. 2008;14(1):61-7.

Kavallaris A, Chalvatzas N, Hornemann A. Subareolar blue dye-only injection for sentinel lymph node biopsy. J Cancer Res Clin Oncol. 2008;134(6):667-72.

Mathelin C, Croce S, Brasse D. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res. 2009;29(10):4119-25.

Golshan M, Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J. 2006;12(5):428-30.

Brahma B, Putri RI, Karsono R. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital. World J Surg Oncol. 2017;15(1):41.

Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2018;13(9):e0204364.

Hermansyah D, Rahayu Y, Azrah A. Accuracy of methylene blue test as single technique for sentinel lymph node biopsy in early stage breast cancer. Asian Pac J Cancer Prev. 2021;22(9):2765-9.

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.